Procyon Private Wealth Partners LLC grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 255.8% during the 3rd quarter, HoldingsChannel reports. The fund owned 4,892 shares of the medical research company’s stock after acquiring an additional 3,517 shares during the period. Procyon Private Wealth Partners LLC’s holdings in Amgen were worth $1,040,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. Regency Capital Management Inc. DE purchased a new position in shares of Amgen during the 1st quarter valued at $27,000. Maverick Capital Ltd. purchased a new position in shares of Amgen during the 1st quarter valued at $27,000. KB Financial Partners LLC acquired a new stake in shares of Amgen in the 1st quarter valued at $35,000. Itau Unibanco Holding S.A. acquired a new stake in shares of Amgen in the 2nd quarter valued at $39,000. Finally, Lumature Wealth Partners LLC lifted its stake in shares of Amgen by 82.3% in the 2nd quarter. Lumature Wealth Partners LLC now owns 175 shares of the medical research company’s stock valued at $43,000 after purchasing an additional 79 shares during the last quarter. Institutional investors and hedge funds own 74.95% of the company’s stock.
Several equities research analysts recently issued reports on AMGN shares. Barclays reduced their price objective on shares of Amgen from $230.00 to $228.00 and set an “equal weight” rating for the company in a research note on Wednesday, November 3rd. Royal Bank of Canada reduced their price objective on shares of Amgen from $217.00 to $216.00 and set a “sector perform” rating for the company in a research note on Wednesday, November 3rd. Daiwa Capital Markets lowered shares of Amgen from an “outperform” rating to a “neutral” rating and set a $220.00 price objective for the company. in a research note on Thursday, September 23rd. SVB Leerink reduced their price objective on shares of Amgen from $234.00 to $216.00 and set a “market perform” rating for the company in a research note on Wednesday, November 3rd. Finally, William Blair reissued a “hold” rating on shares of Amgen in a research report on Friday, September 17th. Two research analysts have rated the stock with a sell rating, ten have assigned a hold rating and six have given a buy rating to the company. According to data from MarketBeat.com, Amgen currently has an average rating of “Hold” and a consensus price target of $235.50.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, November 2nd. The medical research company reported $4.67 EPS for the quarter, beating the Zacks’ consensus estimate of $4.22 by $0.45. Amgen had a net margin of 21.77% and a return on equity of 108.67%. During the same quarter last year, the company earned $4.37 earnings per share. As a group, equities analysts forecast that Amgen Inc. will post 16.83 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 8th. Stockholders of record on Tuesday, November 16th will be given a dividend of $1.76 per share. This represents a $7.04 dividend on an annualized basis and a dividend yield of 3.45%. The ex-dividend date of this dividend is Monday, November 15th. Amgen’s dividend payout ratio is currently 72.50%.
Amgen, Inc is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA.
Recommended Story: Risk Tolerance
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.